Latest Oncology News

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Caroline Seymour

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Kristie L. Kahl

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

Chris Ryan

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

Kristi Rosa

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Ariana Pelosci

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Latest Oncology Videos

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast

Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer

Rechallenge Strategies, Practice Logistics, and Patient Communication Regarding ADCs in Breast Cancer

Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer

Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

Clinical Impact of Datopotamab Deruxtecan in First Line Triple Negative Breast Cancer

CNS Recurrence and the Expanding Role of ADCs in Breast Cancer

Outcomes With Blinatumomab in Younger Adults With BCR:ABL1–negative B-ALL

Emerging Strategies for ALK+ NSCLC

Endometrial Cancer: Interpreting dMMR and Post-Adjuvant Activity from LEAP-001

Assessing Relapse: Clinical, Biological, and Patient-Centered Considerations

All Oncology News

Dr Smith on the Role of Radioligand Therapy in Prostate Cancer

December 4th 2025

Matthew Smith, MD, PhD

Matthew R. Smith, MD, PhD, discusses how radioligand therapies are altering the prostate cancer treatment paradigm.

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis

December 4th 2025

Courtney Flaherty

Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship

December 4th 2025

R. Lor Randall, MD, FACS

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC

December 4th 2025

Kyle Doherty

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

Kyle Doherty

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Loncastuximab Tesirine Plus Glofitamab Yields High CR Rates in DLBCL in Updated LOTIS-7 Analysis

December 4th 2025

Caroline Seymour

Adding loncastuximab tesirine to glofitamab led to activity irrespective of disease status in relapsed/refractory diffuse large B-cell lymphoma.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Riley Kandel

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Researchers Find Ancestry Impacts Effectiveness of Prostate Cancer Drugs

December 4th 2025

Fox Chase Cancer Center, Temple Health

Effectiveness of prostate cancer drugs potentially tied to ancestry according to new research data.

Selecting Candidates for HER2 TKIs

December 4th 2025

Julia Rotow, MD

Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges and responses to chemotherapy and immunotherapy.

Unmet Needs and Future Outlook for HER2-Targeted Therapies

December 4th 2025

Neil M. Iyengar, MD

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Efficacy and Safety Data for CAR T Therapies in Marginal Zone Lymphoma

December 4th 2025

Reem Karmali, MD, MS

Panelists discuss how emerging evidence supports the use of CAR T therapy for patients with relapsed or refractory marginal zone lymphoma.

Zongertinib After ADC Therapy: Efficacy, Safety, and Clinical Context

December 4th 2025

Julia Rotow, MD

Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges, responses, and the importance of monitoring for ILD.

Exciting New Data for TNBC Therapies

December 4th 2025

Neil M. Iyengar, MD

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025

December 4th 2025

Jax DiEugenio

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

Dr Gonzalez-Martin on the Efficacy of TUB-040 in Ovarian Cancer

December 3rd 2025

Antonio Gonzalez-Martin, MD

Antonio Gonzalez-Martin, MD, discusses the key efficacy findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

See All News